Mizuho reaffirmed their top pick rating on shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) in a research report released on Wednesday. Mizuho currently has a $26.00 price target on the specialty pharmaceutical company’s stock.

“We continue to like ADMS into its August 24 PDUFA for Parkinson’s Disease, and we reiterate our Buy rating and our $26 PT.”,” the firm’s analyst commented.

Separately, Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, February 28th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $28.43.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/adamas-pharmaceuticals-inc-adms-given-top-pick-rating-at-mizuho.html

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 17.69 on Wednesday. Adamas Pharmaceuticals has a 12-month low of $12.07 and a 12-month high of $19.50. The company’s market capitalization is $393.05 million. The stock’s 50 day moving average is $16.99 and its 200-day moving average is $16.17.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, February 21st. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.12. Adamas Pharmaceuticals had a negative net margin of 5,267.99% and a negative return on equity of 38.31%. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.17 million. During the same period last year, the company earned ($0.58) earnings per share. The firm’s revenue was down 92.6% compared to the same quarter last year. On average, equities analysts predict that Adamas Pharmaceuticals will post ($3.26) earnings per share for the current fiscal year.

Your IP Address:

A number of institutional investors have recently modified their holdings of the company. Great Point Partners LLC purchased a new position in Adamas Pharmaceuticals during the third quarter valued at approximately $42,688,000. Brenner West Capital Advisors LP increased its position in Adamas Pharmaceuticals by 4.5% in the fourth quarter. Brenner West Capital Advisors LP now owns 1,221,463 shares of the specialty pharmaceutical company’s stock valued at $20,643,000 after buying an additional 52,188 shares during the last quarter. Brenner West Capital Advisors LLC increased its position in Adamas Pharmaceuticals by 15.0% in the third quarter. Brenner West Capital Advisors LLC now owns 1,169,275 shares of the specialty pharmaceutical company’s stock valued at $19,188,000 after buying an additional 152,275 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its position in Adamas Pharmaceuticals by 2.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 571,789 shares of the specialty pharmaceutical company’s stock valued at $9,383,000 after buying an additional 11,910 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in Adamas Pharmaceuticals during the fourth quarter valued at approximately $9,058,000. Institutional investors and hedge funds own 75.44% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

5 Day Chart for NASDAQ:ADMS

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.